Three-Week Monitoring After Anamorelin Initiation in Unresectable or Recurrent Pancreatic Cancer: Dietary Intake Category,Observed Body Weight,and Prognostic Nutritional Index

Abstract

Background:

Monitoring data for anamorelin in pancreatic cancer are limited.

Objective:

To descriptively examine week-three documentation-derived dietary intake category, observed body weight, laboratory-derived prognostic nutritional index (PNI), and treatment continuation after anamorelin initiation.

Methods:

We retrospectively included week-three-evaluable patients with unresectable or recurrent pancreatic cancer who initiated anamorelin at a Japanese hospital (July 2021–October 2024). Dietary intake category was derived from routine documentation. Paired changes used the Wilcoxon signed-rank test.

Results:

Among patients (N = 40; PNI, n = 39), dietary intake was classified as increased in 17, stable in 21, and decreased in 2. Median observed body weight was higher at week three than baseline (51.1 vs. 50.2 kg; p = 0.026), whereas median PNI was lower (38.5 vs. 39.8; p = 0.006). The median time-to-discontinuation was 60 days; 16 patients (40.0%) continued ≥84 days.

Conclusion:

These descriptive findings require cautious multidimensional interpretation; causal treatment effects cannot be inferred.